1 Classification

Inflammatory myopathies are a heterogeneous group of disorders in which immune-mediated muscle injury leads to weakness, reduced endurance, and, in some forms, involvement of skin or other organs. Classification is based on clinical pattern, age at onset, associated antibodies, biopsy findings, and the presence of features outside the muscles. In practice, these categories overlap, and patients may initially resemble more than one subtype.

1.1 Major inflammatory myopathy subtypes

The principal idiopathic inflammatory myopathies are polymyositis, dermatomyositis, inclusion body myositis, and immune-mediated necrotizing myopathy. Each has characteristic clinical and pathological features, although none is entirely uniform. Distinguishing among them is important because expected response to treatment and long-term outlook differ.

1.1.1 Polymyositis

Polymyositis is traditionally described as a symmetric proximal myopathy with inflammatory infiltrates in muscle tissue. It usually causes difficulty rising from a chair, climbing stairs, or lifting objects overhead. Over time, the diagnosis has become more selective because many cases once labeled polymyositis are now recognized as other entities, including overlap myositis or immune-mediated necrotizing myopathy.

1.1.2 Dermatomyositis

Dermatomyositis combines muscle inflammation with distinctive skin findings. Typical manifestations include a violaceous rash on the eyelids, scaly lesions over joints, and photosensitive changes on exposed skin. Muscle involvement may be mild or severe, and the disease can occur in both children and adults. In some patients, skin disease dominates the presentation.

1.1.3 Inclusion body myositis

Inclusion body myositis is usually a slowly progressive myopathy that affects older adults more often than the other inflammatory myopathies. Weakness frequently involves the quadriceps and the finger flexors, producing trouble with stairs, kneeling, grip, or fine hand function. It often responds poorly to immunosuppressive treatment and has a more chronic course than polymyositis or dermatomyositis.

1.1.4 Immune-mediated necrotizing myopathy

Immune-mediated necrotizing myopathy is marked by severe muscle weakness and prominent muscle fiber injury with relatively sparse inflammatory infiltrates on biopsy. It may be associated with specific autoantibodies and can appear after exposure to certain medications or in association with other immune conditions. Blood creatine kinase levels are often markedly elevated, reflecting active muscle damage.

Overlap myositis refers to inflammatory muscle disease occurring alongside another connective tissue disorder, such as systemic sclerosis, lupus, or mixed connective tissue disease. These cases may combine features from multiple autoimmune syndromes, which can complicate diagnosis. Related entities include cancer-associated myositis and myositis with antisynthetase features, both of which may show additional systemic involvement.

1.3 Juvenile forms

Juvenile inflammatory myopathies most often present as juvenile dermatomyositis, though other subtypes can occur. Children may show rash, proximal weakness, muscle tenderness, or difficulty with normal activity. Calcinosis and vasculopathy are more prominent in pediatric disease than in adult forms, and early recognition is important to limit long-term disability.

2 Causes and pathogenesis

Inflammatory myopathy arises from abnormal immune activity directed against muscle tissue, often with a mixture of genetic susceptibility and environmental triggers. The exact pathway differs among subtypes, but most involve immune recognition of muscle or vessel components, followed by tissue damage and impaired muscle function. In some forms, injury is dominated by inflammation; in others, by direct fiber necrosis or chronic degenerative change.

2.1 Autoimmune mechanisms

Autoimmune responses are central to most inflammatory myopathies. T cells, B cells, autoantibodies, and cytokines participate in the attack on muscle fibers, endomysial tissue, or the small blood vessels that supply muscle. Specific autoantibodies can correlate with clinical patterns, such as skin disease, lung involvement, or severe necrotizing injury.

2.2 Muscle fiber injury and inflammation

Muscle damage results from repeated immune-mediated assault on myofibers, which disrupts the architecture needed for contraction. Injured fibers release enzymes and inflammatory signals, further amplifying the process. Persistent inflammation may eventually lead to fiber loss, regeneration attempts, fatty replacement, and reduced strength.

2.3 Genetic and environmental influences

Inherited factors may influence susceptibility, immune regulation, and the likelihood of particular antibody profiles. Environmental contributors can include viral exposures, ultraviolet light in dermatomyositis, and other triggers that promote immune activation in predisposed individuals. The interaction of these factors likely determines why disease develops in some people but not others.

2.4 Drug-induced and secondary causes

Some inflammatory myopathy syndromes are secondary to medications, systemic disease, or malignancy. Certain drugs can trigger muscle injury or unmask an immune response against muscle. Secondary myopathy must be considered when symptoms begin after a new medication, alongside another autoimmune disorder, or in a context where another underlying condition may be driving the process.

3 Signs and symptoms

The clinical picture is shaped by the muscles affected and by any extra-muscular disease. Weakness is usually the most prominent symptom, but fatigue, pain, rash, swallowing difficulty, and respiratory complaints may also appear. Onset may be gradual or subacute, and severity ranges from mild functional limitation to profound disability.

3.1 Muscle weakness patterns

Proximal weakness is the classic pattern in many inflammatory myopathies. Patients often notice trouble standing from a seated position, climbing steps, combing hair, or lifting items above shoulder level. In inclusion body myositis, weakness may be asymmetric and can involve the hands and thigh muscles early in the course.

3.2 Pain, fatigue, and stiffness

Muscle pain is variable and may be mild compared with the degree of weakness. Fatigue and generalized stiffness are common and can reduce activity even when objective strength loss is modest. Some individuals experience exercise intolerance, cramping, or a heavy-limbed sensation that becomes more noticeable during daily tasks.

3.3 Skin manifestations

Skin findings are a defining feature of dermatomyositis. Common lesions include eyelid discoloration, rash over the knuckles, and photosensitive eruptions on the face, chest, or shoulders. Itching, swelling, and skin sensitivity may accompany the rash. In children, skin changes may be accompanied by vascular abnormalities and calcific deposits.

3.4 Swallowing and respiratory involvement

Weakness of the swallowing muscles can cause dysphagia, choking, coughing during meals, or weight loss. Respiratory muscles may be affected in severe cases, leading to shortness of breath or reduced cough strength. When the disease also involves the lungs, breathing symptoms may reflect both muscle weakness and interstitial lung disease.

3.5 Extramuscular features

Inflammatory myopathies can extend beyond skeletal muscle. Joints may become painful or stiff, and some patients develop lung, heart, or esophageal involvement. Fever, weight loss, Raynaud phenomenon, and other systemic symptoms may appear, especially in overlap syndromes or when associated antibodies are present.

4 Diagnosis

Diagnosis relies on combining history, physical examination, laboratory testing, imaging, and pathology. No single test is sufficient in every case, and the workup is often tailored to the patient’s symptoms and likely subtype. Accurate classification helps guide therapy and identify associated complications.

4.1 Clinical evaluation

Clinical assessment begins with the pattern and tempo of weakness, the distribution of affected muscles, and the presence of rash, dysphagia, or respiratory symptoms. The examiner looks for objective proximal weakness, reduced functional performance, and skin or joint findings suggestive of a specific syndrome. Medication history and signs of another systemic illness are also important.

4.2 Laboratory studies

Laboratory testing supports the diagnosis and helps measure disease activity. It may also reveal organ involvement or suggest an alternative explanation for weakness. Serial results are often used to monitor response to treatment.

4.2.1 Muscle enzymes

Serum muscle enzymes, especially creatine kinase, are commonly elevated when active muscle injury is present. Other enzymes, such as aldolase and transaminases, may also rise. The degree of elevation varies by subtype and does not always match symptom severity, particularly in chronic or treated disease.

4.2.2 Autoantibody testing

Autoantibody panels can aid classification and risk assessment. Some antibodies are linked to dermatomyositis, antisynthetase features, necrotizing disease, or overlap syndromes. Results may support the diagnosis, suggest associated lung disease, and help identify patients who need closer surveillance for extramuscular complications.

4.3 Electromyography

Electromyography can show a myopathic pattern with abnormal spontaneous activity, short-duration motor unit potentials, and reduced recruitment. These findings help distinguish inflammatory myopathy from neuropathic disorders or purely structural muscle disease. Although not specific on its own, it can guide biopsy site selection and reinforce the clinical impression.

4.4 Imaging studies

Imaging is useful for detecting active inflammation, selecting a biopsy site, and distinguishing active disease from chronic damage. It is particularly helpful when physical findings are subtle or when the diagnosis remains uncertain after initial tests. Cross-sectional imaging can also help evaluate complications in adjacent structures.

4.4.1 MRI of skeletal muscle

Magnetic resonance imaging of skeletal muscle can reveal edema, inflammation, fatty replacement, and atrophy. Areas with active inflammation often appear bright on fluid-sensitive sequences. MRI is valuable for mapping disease distribution and for identifying muscles that are likely to yield informative biopsy results.

4.5 Muscle biopsy

Muscle biopsy remains an important diagnostic tool, especially when the presentation is atypical or classification is unclear. Histology can show endomysial inflammation, perifascicular atrophy, necrosis with minimal inflammation, rimmed vacuoles, or other characteristic patterns. The biopsy interpretation is most meaningful when integrated with clinical and serologic data.

4.6 Differential diagnosis

Several conditions can resemble inflammatory myopathy, including muscular dystrophies, endocrine myopathies, metabolic disorders, motor neuron disease, drug toxicity, and deconditioning. Infection and steroid-induced weakness may also complicate evaluation. Distinguishing these possibilities matters because treatment and prognosis differ substantially.

5 Treatment

Treatment aims to suppress immune-mediated muscle injury, restore function, and prevent complications. The choice of therapy depends on the subtype, severity, organ involvement, and response to earlier treatment. Rehabilitation and symptom-directed care are usually combined with pharmacologic therapy.

5.1 Corticosteroids

Corticosteroids are often used as initial treatment for active inflammatory myopathy. They can improve strength and reduce inflammation, especially in polymyositis and dermatomyositis. Because long-term steroid exposure carries substantial risks, clinicians usually taper the dose and add steroid-sparing agents when prolonged therapy is needed.

5.2 Immunosuppressive medications

Conventional immunosuppressive drugs are commonly used to maintain control and reduce steroid dependence. Agents such as methotrexate, azathioprine, mycophenolate, and others may be selected according to disease subtype and coexisting organ involvement. Response is typically assessed by symptoms, examination, enzyme levels, and functional improvement.

5.3 Biologic therapies

Biologic and targeted therapies are used in selected patients with refractory or severe disease. These treatments may be considered when conventional agents are insufficient or poorly tolerated. Their use is guided by the myopathy subtype, associated autoantibodies, and the presence of lung or other systemic complications.

5.4 Physical and occupational therapy

Rehabilitation is an essential part of management. Physical therapy helps preserve range of motion, improve endurance, and rebuild strength after inflammation is controlled. Occupational therapy supports safer performance of daily activities and may recommend assistive devices, adaptive techniques, or home modifications.

5.5 Management of complications

Complications may require specific supportive care in addition to immune therapy. Early attention to swallowing, breathing, and skin health can reduce morbidity. Treatment planning is often multidisciplinary.

5.5.1 Dysphagia treatment

Swallowing difficulty may require dietary modification, speech and swallowing therapy, and aspiration precautions. In severe cases, temporary nutritional support may be needed. Careful assessment is important because silent aspiration can occur even when symptoms are modest.

5.5.2 Respiratory support

If respiratory muscles are weak or lung disease is present, patients may need oxygen assessment, ventilatory support, or pulmonary monitoring. Breathing tests can help detect declining function. Prompt treatment of respiratory infection and aspiration risk is important in advanced disease.

5.5.3 Skin care and sun protection

Patients with dermatomyositis benefit from skin-directed care, including moisturizers, topical therapy when needed, and sun avoidance measures. Protective clothing and broad-spectrum sunscreen can reduce photosensitive flares. Managing itch, rash, and skin fragility improves comfort and quality of life.

6 Prognosis

The prognosis varies by subtype, age at onset, treatment responsiveness, and the extent of extramuscular disease. Some patients improve substantially with therapy, while others have a chronic or relapsing course. Long-term outcome is strongly influenced by how early the disorder is recognized and treated.

6.1 Disease course

Disease course may be monophasic, relapsing-remitting, or steadily progressive. Dermatomyositis and immune-mediated necrotizing myopathy often show meaningful treatment response, whereas inclusion body myositis is usually more slowly progressive and less treatment responsive. Chronic muscle damage can remain even after inflammation is controlled.

6.2 Functional outcomes

Functional recovery depends on how much reversible inflammation is present compared with fixed weakness and atrophy. Some individuals regain near-normal daily function, while others continue to need assistance with mobility, lifting, or self-care. Rehabilitation and treatment adherence can improve independence and reduce disability.

6.3 Relapse and long-term monitoring

Relapse is common enough that follow-up is usually prolonged. Monitoring includes strength testing, laboratory studies, medication side effects, and surveillance for organ involvement. Long-term observation is especially important when tapering therapy or when there is concern for pulmonary, swallowing, or cardiac complications.

6.4 Prognostic factors

Important prognostic factors include the specific subtype, severity at presentation, age, delay in diagnosis, autoantibody profile, and response to initial therapy. Lung involvement, marked dysphagia, and extensive muscle damage tend to worsen outlook. In contrast, early treatment and preserved baseline function are associated with better recovery.

7 Epidemiology

Inflammatory myopathies are uncommon but clinically significant because of their potential to cause chronic disability. Epidemiologic patterns differ among subtypes, reflecting variation in age of onset, sex distribution, and associated immune features. The true frequency is sometimes difficult to measure because of evolving diagnostic criteria.

7.1 Incidence and prevalence

Overall incidence is low, and prevalence remains modest compared with more common muscle disorders. Dermatomyositis and polymyositis historically accounted for many cases, though modern classification has redistributed some patients into more specific categories. Inclusion body myositis is an important cause of acquired weakness in older adults despite its relatively low population frequency.

7.2 Age and sex distribution

Dermatomyositis and polymyositis can occur at nearly any age, including childhood, whereas inclusion body myositis usually appears later in life. Many inflammatory myopathies are more frequent in females, although the degree of sex bias varies by subtype. Juvenile disease has its own clinical profile and complication pattern.

7.3 Geographic and population patterns

Reported rates vary across regions, partly because of differences in diagnostic access, study design, and classification methods. Some antibody-defined subgroups show demographic clustering, but broad global patterns are still being clarified. Population-based studies continue to refine estimates of disease burden and subtype distribution.

8 Research and future directions

Research on inflammatory myopathy focuses on improving diagnostic precision, understanding immune mechanisms, and developing therapies that are more selective and less toxic. Newer studies increasingly combine clinical data with serology, imaging, and tissue analysis. The goal is earlier identification of disease subtype and more individualized treatment.

8.1 Biomarkers

Biomarkers are being studied to better measure disease activity, predict response, and detect relapse. Candidate markers include autoantibody profiles, circulating proteins, and molecular signatures in blood or tissue. Reliable biomarkers could reduce dependence on invasive testing and help guide treatment decisions over time.

8.2 Advances in imaging and pathology

Modern imaging techniques are improving visualization of active inflammation and chronic damage. Pathology research is also refining how biopsy patterns are interpreted, especially when samples show overlapping or subtle features. These advances may help separate true inflammatory myopathy from mimicking disorders and may support earlier intervention.

8.3 Targeted and personalized therapies

Future treatment strategies are increasingly aimed at the immune pathways most relevant to a given subtype or antibody profile. Personalized therapy may involve selecting drugs based on predicted response, organ involvement, and risk of adverse effects. As understanding of disease mechanisms improves, management is likely to become more precise and less dependent on broad immunosuppression.